Table 2.
Author | No. of patients | Tumour size | Complete ablation (%) | Treatment failure (%)a | Three-year overall survival | P |
---|---|---|---|---|---|---|
Lencioni et al. [4] | ||||||
RF | 52 | 1 | 91 | 8 | 81 | >0.05 |
PEI | 50 | HCC < 5 cm or 3 HCCs < 3 cm | 82 | 34 | 73 | |
Lin et al. [5] | ||||||
RF | 52 | 1–3 HCCs | 96 | 17 | 74 | 0.014 |
PEI | 52 | <4 cm | 88 | 45 | 50 | |
Shiina et al. [6] | ||||||
RF | 118 | 1–3 HCCs | 100 | 2 | 80 | 0.02 |
PEI | 114 | <3 cm | 100 | 11 | 63 | |
Lin et al. [7] | ||||||
RF | 62 | 1–3 HCCs | 97 | 16 | 74 | 0.031 |
PEI | 62 | <3 cm | 89 | 42 | 51 | |
Brunello et al. [8] | ||||||
RF | 70 | 1–3 HCCs | 96 | 34 | 59 | >0.05 |
PEI | 69 | <3 cm | 66 | 64 | 57 |
aIncludes initial treatment failure (incomplete response) and late treatment failure (local recurrence/progression)